Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Sarepta Therapeutics, Inc. - Common Stock
(NQ:
SRPT
)
16.76
-0.69 (-3.95%)
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 27, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sarepta Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
34
35
Next >
Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program
February 27, 2026
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta Therapeutics to Present New Long-Term and Safety Data Across Gene Therapy and Exon-Skipping Programs at 2026 Muscular Dystrophy Association Clinical & Scientific Congress
February 26, 2026
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Nasdaq, S&P 500 Futures Tread Caution On Nvidia’s China Risk: Why NFLX, WBD, AAPL, CRM, AI, LRMR Are On Traders' Radar Today
↗
February 26, 2026
Data from Stocktwits showed that retail sentiment on SPY and QQQ diverged.
Via
Stocktwits
Topics
Artificial Intelligence
ETFs
Stocks
Sarepta Therapeutics (NASDAQ:SRPT) Posts Q4 Revenue Beat Amid Deep Losses and Major Charges
↗
February 25, 2026
Via
Chartmill
Why Did SRPT Stock Rise 6% In Pre-Market Today?
↗
January 26, 2026
Via
Stocktwits
SRPT Stock Tumbles 12% On Lackluster Preliminary Revenue Numbers Due To Elevidys Safety Concerns
↗
January 12, 2026
Via
Stocktwits
Sarepta Stock Dips After Hours: DMD Drug Blow And CEO Exit Eclipse Q4 Revenue Beat
↗
February 25, 2026
A new Cohort 8 study aims to reopen the non-walking patient market with data expected by the end of 2026.
Via
Stocktwits
Topics
Earnings
Sarepta (SRPT) Q4 2025 Earnings Call Transcript
↗
February 25, 2026
Sarepta (SRPT) Q4 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments
February 25, 2026
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta Therapeutics Announces Commercial Launch of ELEVIDYS in Japan
February 24, 2026
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
February 24, 2026
From
Sarepta Therapeutics, Inc.
Via
Business Wire
SRPT Stock Snaps Hot Winning Streak Ahead Of Q4 Print — What Bear Positioning And Big Money Are Signaling
↗
February 24, 2026
Institutional support remains strong in February, with 134 investors increasing positions and 61 initiating new stakes.
Via
Stocktwits
Topics
Intellectual Property
Sarepta Hits Fresh Hurdle As Court Revives Patent Lawsuit With Regenxbio Over Muscular Disorder Therapy
↗
February 20, 2026
While Sarepta’s gene therapy for the treatment of DMD called Elevidys was approved by the FDA in 2023, Regenxbio is developing its treatment.
Via
Stocktwits
Topics
Intellectual Property
Lawsuit
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results
February 11, 2026
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta Therapeutics Announces Approval of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington’s Disease
February 04, 2026
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients
January 26, 2026
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Which stocks are moving after the closing bell on Friday?
↗
January 23, 2026
Via
Chartmill
Sarepta Therapeutics to Report 3-Year Topline Data from EMBARK Study of ELEVIDYS Gene Therapy in Ambulatory Individuals with Duchenne Muscular Dystrophy
January 23, 2026
From
Sarepta Therapeutics, Inc.
Via
Business Wire
2 Beaten-Down Stocks That Could Sink Even More in 2026
↗
January 21, 2026
Don't catch a falling knife.
Via
The Motley Fool
Topics
Death
Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues
January 12, 2026
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta Therapeutics Announces Submission of Clinical Trial Application for SRP-1005, its Investigational Treatment for Huntington’s Disease
January 07, 2026
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 05, 2026
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 31, 2025
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Why Is SRPT Stock Falling Today?
↗
December 11, 2025
Sarepta Therapeutics announced a debt refinancing plan totaling about $291 million.
Via
Stocktwits
Sarepta Therapeutics Announces Refinancing of Approximately $291 Million of 1.25% Convertible Senior Notes due 2027
December 11, 2025
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Dyne Therapeutics (DYN) Navigates a Paradoxical Day: Positive Clinical Data Overshadowed by Dilution Fears
December 09, 2025
New York, NY – December 9, 2025 – Dyne Therapeutics (NASDAQ: DYN) found itself in an unusual spotlight today, emerging as a significant market mover, albeit in a direction that belied ostensibly...
Via
MarketMinute
Capricor Therapeutics (NASDAQ: CAPR) Soars 535% to Eight-Year High on Landmark Duchenne Muscular Dystrophy Treatment Results
December 03, 2025
December 3, 2025 – Capricor Therapeutics (NASDAQ: CAPR) has sent shockwaves through the biotech sector today, witnessing an astonishing 535% surge in its stock price, propelling the company to an...
Via
MarketMinute
How BridgeBio, A Top 4% Stock, Is Lining Up Dominos On Its Triple-Digit Sprint
↗
December 02, 2025
Shares of BridgeBio Pharma are nearing a record high as the small biotech company takes on drug behemoths Pfizer and Alnylam.
Via
Investor's Business Daily
Sarepta Wins FDA Approval To Begin Study On Reducing Liver Injury Risk With Elevidys
↗
November 25, 2025
The data from the study cohort will be used to determine whether administering sirolimus before and after the ELEVIDYS infusion can help reduce acute liver injury, the company said.
Via
Stocktwits
Sarepta Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne
November 25, 2025
From
Sarepta Therapeutics, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
34
35
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
